These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 18945642

  • 1. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
    Comabella M, Río J, Espejo C, Ruiz de Villa M, Al-Zayat H, Nos C, Deisenhammer F, Baranzini SE, Nonell L, López C, Julià E, Oksenberg JR, Montalban X.
    Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
    [Abstract] [Full Text] [Related]

  • 2. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D.
    Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [Abstract] [Full Text] [Related]

  • 4. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
    Karabudak R, Kurne A, Guc D, Sengelen M, Canpinar H, Kansu E.
    J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
    [Abstract] [Full Text] [Related]

  • 5. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
    Bernal F, Elias B, Hartung HP, Kieseier BC.
    Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
    [Abstract] [Full Text] [Related]

  • 6. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, Kadanka Z, Bednarík J.
    Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis.
    Yılmaz Ü, Gücüyener K, Atak A, Aral A, Gürkaş E, Demir E, Serdaroğlu A.
    Pediatr Neurol; 2012 Sep; 47(3):171-6. PubMed ID: 22883281
    [Abstract] [Full Text] [Related]

  • 9. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Govoni V, Caniatti L, Paolino E, Tola MR, Granieri E, Baricordi OR.
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [Abstract] [Full Text] [Related]

  • 10. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B, Głowińska B, Urban M, Peczyńska J.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Mar; 12(3):184-9. PubMed ID: 17020653
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
    Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfrinato MC, Baldi E, Tola MR, Dallocchio F, Granieri E, Bellini T.
    Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
    [Abstract] [Full Text] [Related]

  • 14. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
    Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, McGee J, Jennings MH, Gonzalez-Toledo E, Minagar A.
    Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
    [Abstract] [Full Text] [Related]

  • 15. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z.
    J Nephrol; 2007 Jul; 20(4):444-52. PubMed ID: 17879211
    [Abstract] [Full Text] [Related]

  • 16. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M.
    Scand J Infect Dis; 2006 Jul; 38(10):867-72. PubMed ID: 17008230
    [Abstract] [Full Text] [Related]

  • 17. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 18. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
    Paśnik J, Cywińska-Bernas A, Moll J, Moll J, Sysa A, Zeman K.
    Przegl Lek; 2009 May; 66(7):359-64. PubMed ID: 20043576
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 20. Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.
    Sellner J, Greeve I, Leib SL, Mattle HP.
    Arch Neurol; 2008 May; 65(5):672-4. PubMed ID: 18474748
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.